(TNYA) Tenaya Therapeutics - Overview
Stock: Gene Therapy, Small Molecule, Cardiomyopathy, Heart Failure, Gene Addition
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 121% |
| Relative Tail Risk | -20.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.48 |
| Alpha | -46.12 |
| Character TTM | |
|---|---|
| Beta | 1.737 |
| Beta Downside | 1.666 |
| Drawdowns 3y | |
|---|---|
| Max DD | 94.92% |
| CAGR/Max DD | -0.36 |
Description: TNYA Tenaya Therapeutics January 19, 2026
Tenaya Therapeutics (NASDAQ:TNYA) is a clinical-stage biotech focused on U.S. cardiovascular gene-therapy solutions. Its lead candidates are TN-201 (AAV-mediated MYBPC3 gene replacement for hypertrophic cardiomyopathy, Phase 2), TN-401 (plakophilin-2 gene therapy for arrhythmogenic right-ventricular cardiomyopathy, Phase 1) and TN-301 (HDAC6 inhibitor for HFpEF, Phase 1). The firm also pursues an AAV-dworf gene therapy for dilated cardiomyopathy and a reprogramming platform targeting post-myocardial-infarction heart failure, leveraging gene editing, silencing, addition and cellular regeneration technologies.
As of the latest 10-Q (Q3 2024), Tenaya reported cash and equivalents of roughly $85 million, giving it an estimated 12-month runway at current burn (~$7 million per month). The company recently closed a $50 million private placement, diluting existing shareholders but extending its development timeline. Its market capitalization hovers around $210 million, reflecting a price-to-cash ratio of ~2.5×, which is modest compared with the broader cardiac-gene-therapy peer set.
The cardiovascular gene-therapy market is projected to grow at a CAGR of 12-15 % through 2030, driven by aging demographics, high unmet need in inherited cardiomyopathies, and favorable reimbursement trends for AAV-based products. Additionally, the U.S. Inflation Reduction Act’s expanded R&D tax credit and the FDA’s accelerated pathways for rare-disease gene therapies provide macro-level tailwinds for Tenaya’s pipeline.
For a deeper quantitative dive into Tenaya’s valuation dynamics, the ValueRay platform offers a concise, data-rich snapshot worth checking out.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.70 > 0.02 and ΔFCF/TA -2.23 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.69 > 3% & CFO -72.7m > Net Income -94.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (163.3m) vs 12m ago 89.58% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 12.56%; Δ -12.56% > 0%) |
| Interest Coverage Ratio: -64.26 > 6 (EBITDA TTM -87.0m / Interest Expense TTM -1.49m) |
Altman Z'' -15.00
| A: 0.46 (Total Current Assets 61.2m - Total Current Liabilities 13.2m) / Total Assets 105.0m |
| B: -5.57 (Retained Earnings -584.8m / Total Assets 105.0m) |
| C: -0.78 (EBIT TTM -95.7m / Avg Total Assets 122.8m) |
| D: -26.45 (Book Value of Equity -584.8m / Total Liabilities 22.1m) |
| Altman-Z'' Score: -48.17 = D |
What is the price of TNYA shares?
Over the past week, the price has changed by -10.01%, over one month by +5.12%, over three months by -43.25% and over the past year by -9.54%.
Is TNYA a buy, sell or hold?
- StrongBuy: 6
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TNYA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 1134.6% |
| Analysts Target Price | 10 | 1134.6% |
| ValueRay Target Price | 0.6 | -21% |
TNYA Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -95.7m USD
EBITDA TTM = -87.0m USD
Long Term Debt = 11.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.93m USD (from shortTermDebt, last quarter)
Debt = 11.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -44.8m USD (from netDebt column, last quarter)
Enterprise Value = 122.9m USD (167.7m + Debt 11.5m - CCE 56.3m)
Interest Coverage Ratio = -64.26 (Ebit TTM -95.7m / Interest Expense TTM -1.49m)
EV/FCF = -1.67x (Enterprise Value 122.9m / FCF TTM -73.5m)
FCF Yield = -59.76% (FCF TTM -73.5m / Enterprise Value 122.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.95m) / Revenue TTM)
Tobins Q-Ratio = 1.17 (Enterprise Value 122.9m / Total Assets 105.0m)
Interest Expense / Debt = 35.71% (Interest Expense 4.12m / Debt 11.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -75.6m (EBIT -95.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.64 (Total Current Assets 61.2m / Total Current Liabilities 13.2m)
Debt / Equity = 0.14 (Debt 11.5m / totalStockholderEquity, last quarter 82.9m)
Debt / EBITDA = 0.51 (negative EBITDA) (Net Debt -44.8m / EBITDA -87.0m)
Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -44.8m / FCF TTM -73.5m)
Total Stockholder Equity = 98.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -76.77% (Net Income -94.3m / Total Assets 105.0m)
RoE = -95.46% (Net Income TTM -94.3m / Total Stockholder Equity 98.7m)
RoCE = -86.84% (EBIT -95.7m / Capital Employed (Equity 98.7m + L.T.Debt 11.5m))
RoIC = -76.61% (negative operating profit) (NOPAT -75.6m / Invested Capital 98.7m)
WACC = 13.34% (E(167.7m)/V(179.3m) * Re(12.32%) + D(11.5m)/V(179.3m) * Rd(35.71%) * (1-Tc(0.21)))
Discount Rate = 12.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 54.61%
Fair Price DCF = unknown (Cash Flow -73.5m)
EPS Correlation: 97.21 | EPS CAGR: 122.3% | SUE: 3.90 | # QB: 1
Revenue Correlation: 2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.13 | Chg30d=+0.013 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.46 | Chg30d=+0.102 | Revisions Net=+3 | Growth EPS=+20.8% | Growth Revenue=+0.0%